RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS

中等风险 RMS 中 VAC 与 VAC 与 VTC 交替的随机研究

• 批准号: 7607495
• 负责人: YOUSIF H MATLOUB
• 金额: $ 0.2万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607495
• 关键词: Chemotherapy-Oncologic Procedure; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Cyclophosphamide/Topotecan/Vincristine; Databases; Drug usage; Funding; Grant; Institution; National Cancer Institute; Patients; Phase III Clinical Trials; Physician Data Query; Randomized; Research; Research Personnel; Resources; Rhabdomyosarcoma; Risk; Source; United States National Institutes of Health; Work; chemotherapy; cyclophosphamide/dactinomycin/vincristine protocol; neoplastic cell; sarcoma

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to further accrual. (Clinical trial summary from the National Cancer Institute's PDQ¿ database) Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma.

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究已关闭，无法进一步累积。 （临床试验总结来自国家癌症研究所的PDQ数据库） 化疗中使用的药物，如更生霉素，环磷酰胺，长春新碱和拓扑替康，使用不同的方式来阻止肿瘤细胞分裂，使它们停止生长或死亡。目前尚不清楚哪种联合化疗方案治疗横纹肌肉瘤更有效。这项随机III期试验比较了两种不同的联合化疗方案，以了解每种方案在治疗未经治疗的横纹肌肉瘤或肉瘤患者中的效果。